Cell Metabolism

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

Retrieved on: 
Thursday, May 2, 2024
Infection, MASH, Liver disease, Cirrhosis, NAFLD, American Gastroenterological Association, NIH, Publication, Research, Cell Metabolism, Yale University, American Liver Foundation, KOL, Journal of Clinical Pathology, Journal, NASH, Virginia Commonwealth University, Liver, Patient, Fibrosis, AASLD, Internal medicine, Medical Center, Division, SAN, VCU, Pharmaceutical industry

The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.

Key Points: 
  • The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.
  • A replay of the webinar will be accessible in the investors section of 89bio’s website following the event.
  • He has also served as Secretary as well as President of the American Association for the Study of Liver Diseases.
  • He has been continuously funded by the NIH since 1995 and is the principal investigator of four active NIH grants.

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Retrieved on: 
Thursday, November 30, 2023
Health, Neurology, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Brain, Safety, Research, Deficit spending, Parkinson's disease, Cell Metabolism, ChromaDex, Disease, Tremor, Stiffness, Nicotinamide adenine dinucleotide, Neuron, Nature Communications, Agonal respiration, Dementia, University, Person, Mitochondrion, Translational research, Haukeland University Hospital, University of Bergen, NAD, Pharmaceutical industry, Medical device, PD

These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.

Key Points: 
  • These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.
  • Current treatment options are limited, and there is a pressing need for innovative approaches to manage the effects of this debilitating neurodegenerative disorder.
  • This study establishes the short-term safety of 3,000 mg NR daily and allows the clinical community to explore high-dose options in future therapeutic trials.
  • Notably, all of Prof. Tzoulis’ clinical research is academically-driven and based largely on public funding.

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

Retrieved on: 
Thursday, August 31, 2023
AWARD, The New England Journal of Medicine, Medical Affairs Bureau, Cell Metabolism, University, MOA, Therapy, Diabetes, T1D, Diabetes Care, STEP, Coronavirus Scientific Advisory Board, CMO, CDO, Eli Lilly, AML, Morris, Publication, Patient, DSM-IV codes, Cancer, Chief medical informatics officer, DURATION, Amylin Pharmaceuticals, Johnson & Johnson, Safety, Disease, Pharmaceutical industry, Endocrinology, Lancet, Pfizer, Osteopathic medicine in Canada

as Chief Medical Officer (CMO).

Key Points: 
  • as Chief Medical Officer (CMO).
  • Steve Morris, M.D., will transition to the new role of Chief Development Officer (CDO), where he will continue to lead clinical development of Biomea’s oncology portfolio, including BMF-219, BMF-500 and several early-stage oncology research candidates.
  • “The addition of Juan to the Biomea Leadership team is an important and exciting event for the company.
  • Our appointment of Juan to lead clinical development of BMF-219 in diabetes is a cornerstone of this strategy,” said Thomas Butler, CEO and Chairman of Biomea.

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

Retrieved on: 
Friday, June 16, 2023
Health, Hospitals, Other Health, General Health, Pharmaceutical, Vitamins, Supplements, Biotechnology, University of Helsinki, Science, Human, Cell Metabolism, University, PD, Heart failure, Metabolism, CERP, Science Advances, NR, Placebo, LVEF, Spinal cord, Research fellow, Clinical trial, Ageing, NAD, University of Oslo, Philip Morris External Research Program, ChromaDex, Research, Brain, Inflammation, Affiliation, Mitochondrion, DSM-IV codes, University of Washington School of Medicine, Trial of the century, Associate, Haukeland University Hospital, University of Bergen, City, Publication, Parkinson's disease, Patient, Division, Heart, University of Copenhagen Faculty of Health and Medical Sciences, University of Oulu, Diabetes, Safety, Copenhagen, Dietary supplement, Pharmaceutical industry, Medical device, Nicotinamide riboside, Cardiology

On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).

Key Points: 
  • On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).
  • On behalf of the ChromaDex family, we are thrilled to commemorate our ChromaDex External Research Program as it celebrates a decade of setting the industry standard for excellence in collaborative research,” said Rob Fried, the CEO of ChromaDex.
  • This approach fosters great trust in the research, as often there is skepticism around industry-funded research in the dietary supplement industry.
  • Today, this unique, industry-leading program has research agreements with over 200 institutions in 31 countries, representing over $95 million in estimated total research value.

Cell Metabolism Features the AMP® Type 2 Diabetes Knowledge Portal as a Valuable Tool for Biomedical Researchers

Retrieved on: 
Tuesday, April 4, 2023
Research, Technology, Genetics, Diabetes, Health Technology, Software, Philanthropy, Health, Foundation, Science, Knowledge, NIDDK, Business development, FNIH, Cell Metabolism, Partnership, American Diabetes Association, Drug development, Broad Institute, University, JDRF, Type 2 diabetes, National Institute of Diabetes and Digestive and Kidney Diseases, Pfizer, University of California, San Diego, Risk, MIT, Doctor of Philosophy, Harvard University, Bangladesh Technical Education Board, Development, Inborn errors of metabolism, Kidney, MD, Patient, Liver, Eli Lilly and Company, Merck, Digestive, T2D, NIH, Disease, Pharmaceutical industry, Sanofi

The Foundation for the National Institutes of Health (FNIH) announces that the Type 2 Diabetes Knowledge Portal ( T2DKP ) is featured in a Cell Metabolism article published today.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) announces that the Type 2 Diabetes Knowledge Portal ( T2DKP ) is featured in a Cell Metabolism article published today.
  • The T2DKP is a publicly available source of genetic datasets dedicated to type 2 diabetes and its related traits.
  • The AMP T2D Knowledge Portal provides software infrastructure to support, combine, and harmonize more than 300 anonymized datasets from research studies around the world.
  • An innovative feature of the portal allows the retrieval of genetic data that complies with European Union data protection requirements.

How High Altitude Changes Your Body's Metabolism

Retrieved on: 
Tuesday, March 7, 2023
Burn, Protein, DSM-IV codes, University of California, San Francisco, SAN, UCSF, Oxygen, Movement, Gladstone Institutes, Cell Metabolism, Research, Metabolism, Carbon, Burns, Obesity, Fats, Animal, Cardiovascular disease, Glucose, Hypercholesterolemia, Blood, Dicarboxylic acid, Hypoxia, Mouse, Coronary artery disease, Risk, Atmosphere, Athlete, Behavior, Human, PET, Biochemistry, Diabetes, Temperature, Doctor of Philosophy, Department of Biochemistry, University of Oxford, Observation, Pharmaceutical industry, Medical imaging, Food preservation, Dietary supplement, Arun Midha, William Ewart Gladstone

SAN FRANCISCO, March 7, 2023 /PRNewswire/ -- Compared to those of us who live at sea level, the 2 million people worldwide who live above 4,500 meters (or 14,764 feet) of elevation—about the height of Mount Rainier, Mount Whitney, and many Colorado and Alaska peaks—have lower rates of metabolic diseases such as diabetes, coronary artery disease, hypercholesterolemia, and obesity.

Key Points: 
  • The work, published in the journal Cell Metabolism, not only helps explain the metabolic differences of people who live at high altitude, but could also lead to new treatments for metabolic disease.
  • "We hope these findings will help us identify metabolic switches that might be beneficial for metabolism even outside of low-oxygen environments."
  • In general, these more lasting changes mirror what has been seen in humans who live at high altitude.
  • "We already see athletes going to train at altitude to improve their athletic performance; maybe in the future, we'll start recommending that people spend time at high altitude for other health reasons," says Midha.

Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

Retrieved on: 
Monday, October 17, 2022
Rubius, Infection, Ribosome, Microbiology, Disease, Therapy, Content discovery platform, Technology, RNA transfection, Growth, Essential amino acid, SANA, NASDAQ, Biology, RNA, Research, Publication, University of Innsbruck, PNAS, Multimedia, Science, Investment, Flagship Pioneering, Protein engineering, University, MRNA, Health, CEO, Ecosystem, Flagship, Cell Metabolism, Springer, David Berry (inventor), Nature Communications, Massachusetts Institute of Technology, Autoimmunity, COVID-19, Language, Leadership, Vaccine, Pharmaceutical industry, Medical device, Fine chemical, Moderna

CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform. 

Key Points: 
  • Under her leadership, Moderna expanded the mechanistic understanding of mRNA design principles underlying current and future mRNA therapeutics, including Moderna's Spikevax mRNA vaccine for COVID-19.
  • "We are excited to have Caroline join us as we boldly establish a first-in-field platform to advance tRNA as a new modality with exceptional and unique therapeutic potential."
  • The company's platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.
  • Alltrna has an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation.

ChromaDex Corporation Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Company, History, EBITDA, U.S. Securities and Exchange Commission, Phytochemical, ChromaDex, Webcast, Patient, Investment, News, NASDAQ, CERP, 250th Tunnelling Company, NAD, COVID-19, Marketing, Adjustment, Research, Securities Act of 1933, Securities Exchange Act of 1934, Awareness, Conference, Tru, Forward-looking statement, Human, Investor relations, Compte rendu, Ageing, Cell Metabolism, Security (finance), GAAP, PD, Twitter, NR, SEC, Growth, Human body, Replay, Clinical trial, Annual report, CEO, Pharmaceutical industry, Mobile phone, Communications satellite

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022.
  • We delivered solid financial results in the first quarter, while strengthening our patent portfolio, and announcing dramatic new scientific research on Niagen(R), said CEO, Rob Fried.
  • Following the quarter, we launched Tru Niagen(R) Immune and ramped up our new TV campaign to encouraging early results.
  • Results of operations for the three months ended March 31, 2022 compared to the prior year quarter
    For the three months ended March 31, 2022 (Q1 2022), ChromaDex reported net sales of $17.3 million, up $2.6 million or 18% compared to the first quarter of 2021 (Q1 2021).

ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World

Retrieved on: 
Thursday, April 14, 2022
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, Transfer, Haukeland University Hospital, Translational research, Board, Vivo, Ageing, Cell Metabolism, Achievement, Neurology, NASDAQ, City of Hope National Medical Center, Annual report, Science, NAD, Brain, Lists of diseases, ChromaDex, MTA, Â, CERP, Energy Independence and Security Act of 2007, Program, Patient, Inflammation, Securities Exchange Act of 1934, Development, Company, Bureau of Oceans and International Environmental and Scientific Affairs, Metabolism, External, City, SEC, Nicotinamide riboside, Multimedia, Industry, University, Securities Act of 1933, Health, PD, Pharmaceutical industry, Medical device, Diabetes, Research

ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer agreements (MTAs) through the ChromaDex External Research Program ( CERP ), featuring ChromaDexs flagship ingredient Niagen (patented nicotinamide riboside, or NR) and other proprietary ingredients.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer agreements (MTAs) through the ChromaDex External Research Program ( CERP ), featuring ChromaDexs flagship ingredient Niagen (patented nicotinamide riboside, or NR) and other proprietary ingredients.
  • Over 235 independent scientists, doctors, and investigators across 182 institutions and 33 countries developed the 250+ MTAs to further research using various ChromaDex materials.
  • We believe the research being done through CERP is making a positive difference and will help communities throughout the world.
  • In 2019, the program was branded as the ChromaDex External Research Program (CERP).

ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)

Retrieved on: 
Wednesday, March 2, 2022
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ageing, PD, Degenerative disease, Neuron, ChromaDex, Harvard Medical School, Patient, Tremor, Neuroimaging, Research, Massachusetts General Hospital, Regulatory affairs, Cell Metabolism, Risk, Neurodegeneration, Dementia, Security (finance), Cytokine, Annual report, Hospital, Mitochondrion, University, Haukeland University Hospital, University of Bergen, Parkinson's disease, NAD, Metabolism, SEC, Company, Disease, Securities Act of 1933, Translational research, Trial of the century, Government budget balance, Neurology, Cerebrospinal fluid, Clinical trial, An Act to exempt a particular class of securities from the Securities and Exchange Act, Respiration (physiology), Drug Quality and Security Act, Brain, Human, NASDAQ, Pharmaceutical industry, Medical device, Medical imaging

The clinical trial was part of the ChromaDex External Research Program (CERP) and investigated the companys proprietary Niagen ingredient (patented nicotinamide riboside, or NR) in patients with Parkinsons disease (PD).

Key Points: 
  • The clinical trial was part of the ChromaDex External Research Program (CERP) and investigated the companys proprietary Niagen ingredient (patented nicotinamide riboside, or NR) in patients with Parkinsons disease (PD).
  • Parkinsons disease is a common neurodegenerative disorder, affecting more than 10 million people worldwide.
  • As such, this study assessed NR as a potential therapeutic strategy targeting mitochondrial function and energy metabolism in PD patients.
  • We look forward to further research aimed at understanding the role of NR supplementation in Parkinsons patients.